| Literature DB >> 24175732 |
Donald W Smith1, Evan W Davies, Erika Wissinger, Rachel Huelin, Louis S Matza, Karen Chung.
Abstract
Cardiovascular disease (CVD) results in half of the non-communicable disease-related deaths worldwide. Rising treatment costs have increased the need for cost-utility models designed to compare the value of new and existing therapies. Cost-utility models require utilities, values representing the strength of preferences for various health states. This systematic literature review aimed to identify and evaluate utilities reported for stroke, myocardial infarction (MI) and angina. In total, 83 unique studies were identified that reported utilities for these events. Approximately two-thirds reported utility values for stroke, and most used the EuroQoL five dimension to derive utilities. Utility values were lower in patients who experienced cardiovascular (CV) events than in patients who did not. The utility estimates for each condition varied greatly, likely due to differences in assessment methodologies and patient populations. This variability must be considered when choosing values for cost-utility models. Comparisons among reported utilities are further complicated by inconsistent CV event definitions.Entities:
Mesh:
Year: 2013 PMID: 24175732 DOI: 10.1586/14737167.2013.841545
Source DB: PubMed Journal: Expert Rev Pharmacoecon Outcomes Res ISSN: 1473-7167 Impact factor: 2.217